Status:
UNKNOWN
Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain
Lead Sponsor:
Abu Dhabi Health Services Company
Conditions:
COVID-19
Eligibility:
All Genders
12+ years
Brief Summary
The United Arab Emirates (UAE), the Kingdom of Bahrain, Kuwait, Oman, and Qatar have authorised sotrovimab for emergency use. Local experience among physicians include recent successful COVID-19 vacci...
Eligibility Criteria
Inclusion
- Adults and paediatric patients (≥ 12 years of age weighing at least 40 kg)
- Mild-to-moderate COVID-19
- Positive results of direct SARS-CoV-2 viral testing
- High risk for progression to severe COVID-19
Exclusion
- Patients who are hospitalised due to COVID-19 before sotrovimab administration
- Patients who require oxygen therapy due to COVID-19 before sotrovimab administration oPatients who received pharmacological treatment including monoclonal antibodies to any components of SARS-CoV-2 virus within 6 months prior to enrolment into the study in retrospective and prospective arms.
Key Trial Info
Start Date :
May 12 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
20000 Patients enrolled
Trial Details
Trial ID
NCT05398718
Start Date
May 12 2022
End Date
December 31 2022
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The National Taskforce for combating COVID-19, Royal Medical Services.
Manama, Bahrain